A Markov model compared no screening, cytology and HPV-cytology co-testing across 30 strategies in Korean women aged 20 and over. Biennial cytology cost 1.8 million won per QALY versus no screening, against a 30 million won threshold. Only 4 of 26 co-testing strategies were on the efficiency frontier, none of them cost-effective. Against biennial cytology, they cost 100.5 to 118.4 million won per QALY. Biennial cytology was optimal in 99.6% of probabilistic simulations. The results are modelled estimates, calibrated to registry incidence and tied to current Korean prices.
Why it is interesting: Even the most efficient co-testing strategy cost over three times Korea's threshold per QALY gained. The model also names the HPV test price at which that strategy's verdict would change.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.